Literature DB >> 22157947

Gestational methylazoxymethanol acetate administration alters proteomic and metabolomic markers of hippocampal glutamatergic transmission.

Daniel J Lodge1, Anthony A Grace.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22157947      PMCID： PMC3242322          DOI： 10.1038/npp.2011.255

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN： 0893-133X            Impact factor:   7.853


× No keyword cloud information.
  8 in total

Review 1.  Glutamatergic mechanisms in schizophrenia.

Authors:  Guochuan Tsai; Joseph T Coyle
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

2.  A novel α5GABA(A)R-positive allosteric modulator reverses hyperactivation of the dopamine system in the MAM model of schizophrenia.

Authors:  Kathryn M Gill; Daniel J Lodge; James M Cook; Shamim Aras; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2011-05-11       Impact factor: 7.853

3.  Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia.

Authors:  Ornella Valenti; Pierangelo Cifelli; Kathryn M Gill; Anthony A Grace
Journal:  J Neurosci       Date:  2011-08-24       Impact factor: 6.167

4.  Hippocampal interneurons are abnormal in schizophrenia.

Authors:  Christine Konradi; C Kevin Yang; Eric I Zimmerman; Kathryn M Lohmann; Paul Gresch; Harry Pantazopoulos; Sabina Berretta; Stephan Heckers
Journal:  Schizophr Res       Date:  2011-07-13       Impact factor: 4.939

5.  Correlations between rCBF and symptoms in two independent cohorts of drug-free patients with schizophrenia.

Authors:  Adrienne C Lahti; Martin A Weiler; Henry H Holcomb; Carol A Tamminga; William T Carpenter; Robert McMahon
Journal:  Neuropsychopharmacology       Date:  2006-01       Impact factor: 7.853

6.  Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Behav Brain Res       Date:  2009-02-02       Impact factor: 3.332

7.  A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Margarita M Behrens; Anthony A Grace
Journal:  J Neurosci       Date:  2009-02-25       Impact factor: 6.167

8.  The methylazoxymethanol acetate (MAM-E17) rat model: molecular and functional effects in the hippocampus.

Authors:  Eva Hradetzky; Thomas M Sanderson; Tsz M Tsang; John L Sherwood; Stephen M Fitzjohn; Viktor Lakics; Nadia Malik; Stephanie Schoeffmann; Michael J O'Neill; Tammy Mk Cheng; Laura W Harris; Hassan Rahmoune; Paul C Guest; Emanuele Sher; Graham L Collingridge; Elaine Holmes; Mark D Tricklebank; Sabine Bahn
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853
  8 in total
  4 in total

Review 1.  Structural and Functional Deviations of the Hippocampus in Schizophrenia and Schizophrenia Animal Models.

Authors:  David Wegrzyn; Georg Juckel; Andreas Faissner
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

Review 2.  Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system.

Authors:  Oliver Gruber; Antonella Chadha Santuccione; Helmut Aach
Journal:  Front Psychiatry       Date:  2014-04-03       Impact factor: 4.157

Review 3.  Genotoxic Damage During Brain Development Presages Prototypical Neurodegenerative Disease.

Authors:  Glen E Kisby; Peter S Spencer
Journal:  Front Neurosci       Date:  2021-12-02       Impact factor: 4.677

4.  The Antioxidant N-Acetyl-L-Cysteine Restores the Behavioral Deficits in a Neurodevelopmental Model of Schizophrenia Through a Mechanism That Involves Nitric Oxide.

Authors:  Ana Lopes-Rocha; Thiago Ohno Bezerra; Roberta Zanotto; Inda Lages Nascimento; Angela Rodrigues; Cristiane Salum
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.